基于超高效液相色谱-质谱的代谢组学在肝脏疾病生物标志物发现中的作用

周玄; 赖泳

doi:10.3969/j.issn.1001-5256.2017.05.040

基于超高效液相色谱-质谱的代谢组学在肝脏疾病生物标志物发现中的作用

DOI: 10.3969/j.issn.1001-5256.2017.05.040

周玄,
赖泳

1. 大理大学药学与化学学院药理学教研室
2. 云南省昆虫生物医药研发重点实验室

基金项目:

国家自然科学基金资助项目(81241139,81360511)；

详细信息

中图分类号: R575
计量
- 文章访问数: 2030
- HTML全文浏览量: 25
- PDF下载量: 448
- 被引次数: 0
出版历程
- 出版日期: 2017-05-20

Research advances in the identification of clinical biomarkers for liver diseases using metabolomics based on ultra-performance liquid chromatography-mass spectrometry

Zhou Xuan,
Lai Yong

Department of Pharmacology, College of Pharmacy and Chemistry, Dali University

Research funding:

摘要

摘要:
目前已有的肝脏疾病早期诊断的标志物往往敏感度和特异度较差,因此找到可应用于临床肝脏疾病早期诊断的﹑灵敏度和特异度高的生物标志物十分重要。新兴的代谢组学技术已获得广泛应用,有助于实现这一目标。对近年来基于超高效液相色谱-质谱的代谢组学在肝脏疾病生物标志物发现中的研究作一总结,并强调了其在肝病临床诊断﹑治疗及预后中的重要意义。
- 肝疾病 /
- 代谢组学 /
- 生物学标记 /
- 超高效液相色谱-质谱 /
- 综述
Abstract:
The biomarkers currently known for the early diagnosis of liver diseases often have poor sensitivities and specificities, and thus it is very important to find new biomarkers with high sensitivities and specificities for the early diagnosis of liver diseases.The emerging metabolomics technology has been widely used and may help to achieve this goal.This article reviews the research advances in the role of metabolomics based on ultra-performance liquid chromatography-mass spectrometry in the identification of biomarkers for liver diseases and emphasizes its significance in the early diagnosis, treatment, and prognosis evaluation of liver diseases.
- liver diseases /
- metabonomics /
- biological markers /
- ultra-performance liquid chromatography-mass spectrometry /
- review

HTML全文

参考文献(28)

[1]SCHUPPAN D, AFDHAL NH.Liver cirrhosis[J].Lancet, 2008, 371 (9615) :838-851.

[2]ZHANG A, SUN H, YAN G, et al.Mass spectrometry-based metabolomics:applications to biomarker and metabolic pathway research[J].Biomed Chromatogr, 2015, 30 (1) :7-12.

[3]KOHLER I, GIERA M.Recent advances in liquid-phase separations for clinical metabolomics[J].J Sep Sci, 2017, 40 (1) :93-108.

[4]ALONSO A, MARSAL S, JULIA A.Analytical methods in untargeted metabolomics:state of the art in 2015[J].Front Bioeng Biotechnol, 2015, 3 (23) :23.

[5]RODRIGUEZ-ALLE M, GURNY R, VEUTHEY JL, et al.Coupling ultra high-pressure liquid chromatography with mass spectrometry:constraints and possible applications[J].J Chromatogr A, 2013, 1292:2-18.

[6]ZHAO YY, WU SP, LIU S, et al.Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications[J].Chem Biol Interact, 2014, 220:181-192.

[7]YANG XX, MA H.Research advances in tumor markersof hepatocellular carcinoma[J].J Clin Hepatol, 2016, 32 (4) :811-815. (in Chinese) 杨霄霄, 马红.肝细胞癌肿瘤标志物的研究进展[J].临床肝胆病杂志, 2016, 32 (4) :811-815.

[8]LIAN MJ, LIU SY.Research advances in the application of metabolomics in identifying markers for hepatocellular carcinoma[J].Chin J Clin Lab Sci, 2014, 32 (8) :600-602. (in Chinese) 练明建, 刘树业.代谢组学在肝细胞肝癌标志物中的研究进展[J].临床检验杂志, 2014, 32 (8) :600-602.

[9]LI YD, KUANG ZP.Application of metabolomics technology in screening out markers for liver cancer[J].Chin J Oncol Prev Treat, 2015, 7 (4) :300-302. (in Chinese) 黎远冬, 匡志鹏.代谢组学技术在筛选肝癌标志物中的应用[J].中国癌症防治杂志, 2015, 7 (4) :300-302.

[10]HUANG Q, TAN Y, YIN P, et al.Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics[J].Cancer Res, 2013, 73 (16) :4992-5002.

[11]ZHANG A, SUN H, YAN G, et al.Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid chromatography coupled with high-definition mass spectrometry[J].Clin Chim Acta, 2013, 418:86-90.

[12]CHEN J, WANG W, LV S, et al.Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations[J].Anal Chim Acta, 2009, 650 (1) :3-9.

[13]QIAN X, ZHAN Q, LV L, et al.Steroid hormone profiles plusα-fetoprotein for diagnosing primary liver cancer by liquid chromatography tandem mass spectrometry[J].Clin Chim Acta, 2016, 457:92-98.

[14]FITIAN AI, NELSON DR, LIU C, et al.Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS[J].Liver Int, 2014, 34 (9) :1428-1444.

[15]LIAN JS, LIU W, HAO SR, et al.A serum metabonomic study on the difference between alcohol-and HBV-induced liver cirrhosis by ultra performance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry[J].Chin Med J (Engl) , 2011, 124 (9) :1367-1373.

[16]WANG X, WANG X, XIE G, et al.Urinary metabolite variation is associated with pathological progression of the post-hepatitis B cirrhosis patients[J].J Proteome Res, 2012, 11 (7) :3838-3847.

[17]YANG T, ZHENG XY, XING F, et al.Serum metabolomic characteristics of patients with liver cirrhotic ascites[J].Integr Med Int, 2014, 1 (1) :135-142.

[18]TANG YM, WANG JP, BAO WM, et al.Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis[J].Int J Mol Med, 2015, 36 (2) :377-385.

[19]LIAN JS, LIU W, HAO SR, et al.A serum metabolomic analysis for diagnosis and biomarker discovery of primary biliary cirrhosis and autoimmune hepatitis[J].Hepatobiliary Pancreat Dis Int, 2015, 14 (4) :413-421.

[20]ZHANG A, SUN H, HAN Y, et al.Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system[J].PLo S One, 2013, 8 (5) :e64381.

[21]NIE CY, HAN T, ZHANG L, et al.Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS[J].J Viral Hepat, 2014, 21 (1) :53-63.

[22]LIAN J, LI X, WANG Y, et al.Metabolite variations between acute-on-chronic liver failure and chronic liver failure caused by hepatitis B virus based on ultra-performance liquid chromatography mass spectrometry[J].Biomed Pharmacother, 2016, 84:994-1000.

[23]GARCA-CANAVERAS JC, DONATO MT, CASTELL JV, et al.Acomprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations[J].J Proteome Res, 2011, 10 (10) :4825-4834.

[24]KALHAN SC, GUO L, EDMISON J, et al.Plasma metabolomic profile in nonalcoholic fatty liver disease[J].Metabolism, 2011, 60 (3) :404-413.

[25]BARR J, VZQUEZ-CHANTADA M, ALONSO C, et al.Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease[J].J Proteome Res, 2010, 9 (9) :4501-4512.

[26]CHEN Y, LI C, LIU L, et al.Serum metabonomics of NAFLD plus T2DM based on liquid chromatography-mass spectrometry[J].Clin Biochem, 2016, 49 (13-14) :962-966.

[27]SEIJO S, LOZANO JJ, ALONSO C, et al.Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension[J].Am J Gastroenterol, 2013, 108 (6) :926-932.

[28]SEIJO S, LOZANO JJ, ALONSO C, et al.Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension[J].Liver Int, 2016, 36 (7) :1051-1058.

施引文献

资源附件(0)

访问统计